company background image
ALKEM logo

Alkem Laboratories NSEI:ALKEM Stok Raporu

Son Fiyat

₹5.58k

Piyasa Değeri

₹667.6b

7D

1.1%

1Y

22.5%

Güncellenmiş

23 Nov, 2024

Veri

Şirket Finansalları +

Alkem Laboratories Limited

NSEI:ALKEM Stok Raporu

Piyasa değeri: ₹667.6b

ALKEM Stoklara Genel Bakış

Bir ilaç şirketi olan Alkem Laboratories Limited, Hindistan'da, Amerika Birleşik Devletleri'nde ve uluslararası alanda ilaç ve nutrasötik ürünlerin araştırma ve geliştirme, üretim ve satışını yapmaktadır. Daha fazla detay

Alkem Laboratories Limited Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Alkem Laboratories
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı₹5,583.35
52 Haftanın En Yüksek Seviyesi₹6,439.90
52 Haftanın En Düşük Seviyesi₹4,407.05
Beta0.41
11 Aylık Değişim-6.33%
3 Aylık Değişim-2.96%
1 Yıllık Değişim22.50%
33 Yıllık Değişim56.71%
5 Yıllık Değişim175.16%
Halka arzdan bu yana değişim304.09%

Son Haberler & Güncellemeler

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Nov 15
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Recent updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Nov 15
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Sep 24
What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Sep 03
Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13
Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13
Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13
Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01
Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22
Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Jan 17
Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Dec 27
We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Sep 14
Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Aug 02
Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Jul 07
Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

May 22
Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt

Mar 27
We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Dec 26
Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well

Sep 20
These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well

Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00

Jul 27
Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 13
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

May 23
Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Mar 06
Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Feb 21
Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Hissedar Getirileri

ALKEMIN PharmaceuticalsIN Pazar
7D1.1%0.5%0.5%
1Y22.5%42.5%27.5%

Getiri vs. Endüstri: ALKEM geçen yıl % 42.5 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: ALKEM geçen yıl % 27.5 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ALKEM's price volatile compared to industry and market?
ALKEM volatility
ALKEM Average Weekly Movement3.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.0%

İstikrarlı Hisse Senedi Fiyatı: ALKEM son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ALKEM 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
197317,432Vikas Guptawww.alkemlabs.com

Bir ilaç şirketi olan Alkem Laboratories Limited, Hindistan'da, Amerika Birleşik Devletleri'nde ve uluslararası alanda ilaç ve nutrasötik ürünlerin araştırma ve geliştirme, üretim ve satışını yapmaktadır. Şirket, anti-enfektif, gastro-intestinal, ağrı/analjezik, anti-diyabetik, nöro/merkezi sinir sistemi, jinekoloji, solunum, dermatoloji ve kalp hastalıklarını içeren akut ve kronik terapötik alanlarda markalı jenerik ilaçlar, jenerik ilaçlar, aktif farmasötik bileşenler ve biyobenzerler ve nutrasötikler sunmaktadır. Ayrıca vitaminler, mineraller ve besinlerin yanı sıra ağız yıkama, şampuanlar, gebelik tespit kitleri ve prezervatifler de sunmaktadır.

Alkem Laboratories Limited Temel Bilgiler Özeti

Alkem Laboratories'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ALKEM temel i̇stati̇sti̇kler
Piyasa değeri₹667.57b
Kazançlar(TTM)₹21.22b
Gelir(TTM)₹128.32b

31.5x

F/K Oranı

5.2x

P/S Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ALKEM gelir tablosu (TTM)
Gelir₹128.32b
Gelir Maliyeti₹48.19b
Brüt Kâr₹80.13b
Diğer Giderler₹58.90b
Kazançlar₹21.22b

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)177.50
Brüt Marj62.44%
Net Kâr Marjı16.54%
Borç/Özkaynak Oranı10.4%

ALKEM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.7%

Mevcut Temettü Verimi

3%

Ödeme Oranı